drugset / Trial / NCT00356772

Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

NCT00356772

Phase 1 Completed Laboratoires Thea
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation. To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7

Timeline

Start
2003-02
Primary completion
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 1.5 % Topical
Subject Azithromycin Small molecule 1 g Topical